Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LENTI-HCC-01
- Development stage
- Preclinical
- Lead developer
- Theravectys
- Modality
- Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intramuscular
01
Overview
LENTI-HCC-01 is a preclinical-stage, non-integrative lentiviral vector-based therapeutic vaccine being developed by Theravectys for the treatment of Hepatitis B virus (HBV)-induced hepatocarcinoma (hepatocellular carcinoma). Utilizing Theravectys's proprietary lentiviral vector platform, LENTI-HCC-01 is designed to target and transduce dendritic cells in vivo, leading to the endogenous presentation of encoded HBV antigens (such as the envelope, polymerase, core, and X proteins). This transduction elicits a robust, antigen-specific cellular immune response, particularly driving the activation of cytotoxic CD8+ T cells to eliminate HBV-infected cells and HBV-induced tumor cells.
- Other names
- LENTI-HCC01LENTI-HCC-01LENTI-HCC 01
02
Targets
HBx (Hepatitis B virus X protein)HBc (Hepatitis B virus core protein)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on LENTI-HCC-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LENTI-HCC-01.